Return to homepagePandemic Pact

Immune-Signature to Evaluate COVID-19-Related Liver Injury and Outcomes

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    -99

  • Known Financial Commitments (USD)

    $0

  • Funder

    University of Minnesota

  • Principal Investigator

    MD. Jose Debes, MS. Thomas Leventhal

  • Research Location

    United States of America

  • Lead Research Institution

    Medical School, University of Minnesota

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Between 14% and 53% of patients infected with COVID-19 present with acute liver injury. In patients who have died from COVID-19, incidence of liver injury reached 78%, indicating a potential association between COVID-19-related liver disease and mortality. The pathophysiology underlying liver disease during COVID-19 infection is not understood. However, previous data from SARS studies and a single pathology report on COVID-19 indicate that the virus is non-cytopathic in liver cells, suggesting that the hepatic damage is likely immune-mediated. Co-led by Jose Debes, MD, MS, assistant professor of infectious diseases and international medicine, and Thomas Leventhal, MD, assistant professor of gastroenterology, hepatology and nutrition, this study will assess blood samples from COVID-19 patients aiming to predict the development of acute liver injury, predict COVID-19-related mortality and outcomes, and provide insights in the immune-pathology of COVID-19-related liver disease.